Mosa Meat

Mosa Meat carries the founding legacy of the entire cultivated-meat industry — co-founder Mark Post unveiled the world's first lab-grown burger in 2013 — and it has translated that pedigree into the most advanced regulatory position in European cultivated beef. In January 2025 it filed the EU's first-ever cultivated-beef application, submitting a nearly 1,000-page dossier (two years of work) to European regulators for its cultivated beef fat, and it has filed in parallel across Singapore, the UK, and Switzerland, expecting the UK to grant the first approval. Filing for fat rather than whole muscle is a deliberately shrewd read of EFSA's ingredient-by-ingredient assessment process, mirroring the low-inclusion hybrid strategy that is proving the fastest route to market. On the technical side, Mosa says it has cut the cost of its first burger by roughly 99.999% since 2013, developed an animal-component-free (serum-free) growth medium, and operates bioreactors up to 1,000-liter scale in Maastricht. A December 2025 raise of about €15M ($17.6M) extended its runway into 2028 and came alongside aggressive cost reductions, and total funding now exceeds $135M with backers including Invest-NL, LIOF, the PHW Group, and Just Eat Takeaway founder Jitse Groen. As the leading European name with first-in-line regulatory filings across four jurisdictions, Mosa is positioned to be first to market whenever Western approvals arrive.

Mosa Meat's own strategy telegraphs the industry's predicament: after twelve years and $135M+, the company is seeking approval for *fat as an ingredient* rather than the whole cultivated burger it became famous for, because whole-cut cultivated beef remains economically and technically out of reach. The EU regulatory path it pioneered is also its biggest liability — EFSA review is expected to take around 18 months from the January 2025 filing, and Europe is the hardest cultivated-meat environment in the world: Italy has banned cultivated meat outright, and several EU member states have pushed for restrictions, so even a successful EFSA opinion faces a politicized member-state landscape. The December 2025 raise — only about €15M, explicitly paired with cost-cutting and framed as extending runway "amid sector shake[out]" — signals a company conserving cash in a hostile funding market, not one scaling toward production. Serum-free media and 1,000-liter bioreactors are meaningful but still far short of the millions of liters and pennies-per-gram cost structure that price parity with conventional beef requires, and no cultivated-meat company anywhere has closed that gap. Total capital of $135M is a fraction of what a commercial-scale facility costs. Mosa may hold the regulatory pole position in Europe, but pole position in a market that regulators, politicians, and unit economics are all conspiring to keep small is a thin prize.